2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 106

Atypical manifestations and main misdiagnoses of Takayasu’s arteritis in childhood: a multicenter study of 71 patients
Abstract Number: 107

Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis
Abstract Number: 108

Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil
Abstract Number: 109

Clinical features of pediatric Behçet’s disease patients in Japan
Abstract Number: 110

Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases
Abstract Number: 111

Eosinophilic Fasciitis in Children: Clinical Course and Response to Treatment from Two Large Academic Centers
Abstract Number: 112

Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder
Abstract Number: 113

Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis
Abstract Number: 114

Clinical Features and Treatment Outcomes in Down’s Arthropathy
Abstract Number: 115

Anti-Phospholipid Antibodies in Children with Down Syndrome
Abstract Number: 116

Arthritis as First Presenting Symptom of Inflammatory Bowel Disease: A Case Control Study
Abstract Number: 117

The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy
Abstract Number: 118

Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease
Abstract Number: 119

Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey
Abstract Number: 120

Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].